142280.KQ Green Cross Medical Science Corporation
- Market cap
- KRW 73.9B
- P/E
- -
- P/B
- 1.37x
- ROE
- -14.4%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 142280.KQ undervalued?
Graham numberThe Graham number of Green Cross Medical Science Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Green Cross Medical Science Corporation fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-14.4%), below 10%.
ROA 0/1
Return on assets (-8.0%) is below the industry median (6.2%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (2.2%) is above the 5-year average (-12.0% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (2.2%) is above the industry median (0.5%).
Revenue Growth 0/2
Revenue shrank 1.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.4x) is above the industry median (0.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Green Cross Medical Science Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-…
Full company profileGreen Cross Medical Science Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Green Cross Medical Science Corporation annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 86.2B | 98.4B | 86.3B | 94.1B | 113B | 102B | 113B | 94.0B | 104B | 108B | 101B |
| Gross Profit | 12.5B | 15.4B | 8.18B | 9.47B | 19.8B | 1.67B | 12.8B | 14.0B | 14.9B | 15.2B | 13.5B |
| Operating Income | -2.12B | -732M | -9.01B | -9.54B | 4.20B | -20.2B | -1.26B | 1.80B | 1.60B | 2.89B | 2.07B |
| EBITDA | - | - | - | - | - | - | 4.03B | 9.03B | 10.0B | 8.73B | -3.02B |
| Net Income | -1.89B | -1.35B | -10.7B | -16.2B | 6.72B | -21.2B | -3.58B | 1.80B | 3.58B | 3.67B | -7.78B |
| EPS | -175 | -121 | -962 | -769 | 319 | -1,006 | -170 | 85 | 165 | 169 | -358 |
| Balance Sheet | |||||||||||
| Total Assets | 63.6B | 60.5B | 64.0B | 88.9B | 106B | 95.6B | 96.5B | 90.5B | 88.0B | 90.5B | 96.9B |
| Total Liabilities | 36.8B | 37.3B | 48.6B | 39.3B | 49.1B | 59.5B | 63.2B | 53.6B | 46.8B | 44.1B | 40.9B |
| Shareholders' Equity | 26.8B | 23.2B | 15.3B | 49.6B | 56.5B | 36.1B | 33.3B | 34.5B | 41.2B | 44.4B | 54.0B |
| Cash & Short-term Investments | 2.46B | 3.61B | 8.96B | 13.7B | 4.50B | 1.84B | 10.8B | 5.74B | 678M | 373M | 261M |
| Total Debt | - | 9.80B | 24.5B | 8.59B | 15.8B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.2B | 3.11B | -517M | -4.11B | -8.76B | -18.2B | 10.9B | 4.24B | 3.66B | 7.20B | -1.75B |
| Capital Expenditure | 1.89B | 1.11B | 5.10B | 22.5B | 2.55B | 3.60B | 3.43B | 5.63B | 3.22B | 4.90B | 1.95B |
| Free Cash Flow | - | - | - | - | -11.3B | -21.8B | 7.38B | -1.64B | 384M | 2.30B | -3.70B |
| Ratios | |||||||||||
| ROE | -7.0% | -5.8% | -69.8% | -32.7% | 11.9% | -58.7% | -10.8% | 5.2% | 8.7% | 8.3% | -14.4% |
| ROA | -3.0% | -2.2% | -16.7% | -18.2% | 6.4% | -22.2% | -3.7% | 2.0% | 4.1% | 4.1% | -8.0% |
| Net Profit Margin | -2.2% | -1.4% | -12.4% | -17.2% | 5.9% | -20.9% | -3.2% | 1.9% | 3.4% | 3.4% | -7.7% |
| Debt to Equity | - | 0.42x | 1.60x | 0.17x | 0.28x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Green Cross Medical Science Corporation dividends
Green Cross Medical Science Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 2683:2206 on Sep 30, 2019.
Who owns Green Cross Medical Science Corporation
- Insiders 47.00%
- Institutions 0.15%
- Public & others 52.85%
- Shares outstanding 24.0M
- Free float 12.6M
Green Cross Medical Science Corporation company profile
- Company name
- Green Cross Medical Science Corporation
- Ticker
- 142280.KQ
- ISIN
- KR7142280007
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 134
- Fiscal year end
- December
- Address
- GCMS, Yongin-Si, South Korea, 446-770
- Phone
- 82 8 0297 9000
- Website
- greencrossms.com
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol. The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and " GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo. Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis. The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.
Green Cross Medical Science Corporation management
1- Sagong YoungheePresident